Medacta Group (MOVE.SW) Stock Price
Medacta Group Price
Over the last 9 years Medacta Group grew revenue by 13.5% annually, reaching 681.46 M EUR. Earnings per share have grown at 10.4% per year over the last 9 years. For Medacta Group, the net margin of 14.1% is broadly stable versus 14.4% a few years ago. At today's price the dividend yield works out to roughly 0.28%. The payout ratio is around 8% of earnings. The dividend has grown at 8.8% per year over the past 3 years. The consensus 12-month price target for Medacta Group is 176.05 EUR, about 43.8% above where the stock trades today. Of 11 analysts, 9 rate the stock a buy — an overall Buy consensus.
Medacta Group stock price
Medacta Group business model & stock analysis
Frequently asked questions about Medacta Group
Medacta Group SA operates under a medical technology business model. As a leading manufacturer in the orthopedic industry, Medacta specializes in designing, developing, and distributing innovative surgical solutions. The company is primarily focused on providing integrated solutions for joint replacement, spine surgery, and sports medicine. Medacta aims to improve patient outcomes by offering a comprehensive range of products, including implants, instruments, and computer-assisted technologies. With a commitment to research and development, Medacta continuously pushes the boundaries of medical technology, enabling healthcare professionals to deliver advanced and personalized care to patients worldwide.
Medacta Group SA is primarily active in the medical industry. As an innovative medical device company, Medacta specializes in developing and manufacturing orthopedic implants and surgical instruments. With a focus on personalized solutions, the company offers products for various medical procedures, including joint replacement, spine surgery, and sports medicine. Leveraging advanced technologies and research expertise, Medacta aims to improve patient outcomes and enhance surgical techniques. With its unwavering commitment to innovation and quality, Medacta Group SA has established itself as a prominent player in the medical field.
The main competitors of Medacta Group SA in the market are other companies in the orthopedic medical device industry, such as Zimmer Biomet Holdings Inc., Stryker Corporation, and Johnson & Johnson. These companies also specialize in producing and marketing orthopedic implants and surgical instruments. Medacta Group SA faces competition from these established players, but it differentiates itself through its innovative product offerings, strong focus on customer satisfaction, and dedication to continuous research and development. Its commitment to providing high-quality orthopedic solutions positions Medacta Group SA as a leading player in the market.
Medacta Group SA is a leading Swiss medical device company specializing in orthopedic products and services. Founded in 1999 by Dr. Alberto Siccardi, Medacta has grown to become a trusted player in the global healthcare industry. The company focuses on developing innovative solutions for joint replacement, spine surgery, and sports medicine. With a strong commitment to research and development, Medacta has revolutionized surgical approaches and attained international recognition. Medacta's dedication to providing surgeons with state-of-the-art tools and patients with improved outcomes has led to its global success. As a reputable supplier in the medical field, Medacta Group SA continues to strive for excellence in its products and services for the benefit of patients worldwide.
Medacta Group SA has achieved several significant milestones. Firstly, the company has successfully expanded its global presence, operating in over 50 countries worldwide. Additionally, Medacta Group SA has demonstrated continuous innovation in the field of medical devices and orthopedic solutions. The company has received numerous accolades for its cutting-edge technologies and advanced research initiatives. Medacta Group SA has also shown resilience during challenging times, maintaining steady growth in revenue and market share. Overall, the company's commitment to excellence and dedication to improving patient outcomes have positioned Medacta Group SA as a trusted leader in the healthcare industry.
Medacta Group SA is primarily present in Europe, the United States, and Asia. The company has a strong presence in countries such as Switzerland, Italy, Germany, France, Spain, the United Kingdom, and the Netherlands. Additionally, Medacta Group SA has established a significant footprint in North America, with a focus on the United States. The company's presence in Asia includes countries like Japan, China, South Korea, Malaysia, and Singapore. Medacta Group SA's global presence enables it to provide its innovative medical solutions and orthopedic products to a wide range of healthcare professionals and patients around the world.
Medacta Group SA represents values of innovation, excellence, and patient-centricity in the healthcare industry. As a leading medical device company, Medacta focuses on developing and providing cutting-edge surgical solutions to enhance patient outcomes and improve the quality of life. The company's corporate philosophy revolves around collaboration, integrity, and a strong commitment to continuous improvement. Medacta strives to establish long-term partnerships with surgical teams, ensuring the highest standards of safety and efficiency. By consistently prioritizing patient well-being and leveraging its technological expertise, Medacta Group SA remains at the forefront of advancing medical advancements and delivering top-notch surgical solutions globally.
Analysts currently set an average price target of 181.08 EUR for the Medacta Group stock (median: 176.05 EUR), implying +47.9 % versus the latest price. The consensus is based on 11 analyst ratings.
11 analysts currently rate the Medacta Group stock: 9 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Medacta Group to generate revenue of 765.51 M EUR and earnings per share of 4.90 EUR.
The Medacta Group share (MOVE.SW) is listed on 7 stock exchanges, including: London (0A05.L), SIX (Zürich) (MOVE.SW), Frankfurt (6MD.F), München (6MD.MU), Düsseldorf (6MD.DU).
Medacta Group SA is a leading medical technology company specializing in the development, production, and marketing of innovative surgical solutions. The company operates globally and offers products and services in various business areas including orthopedics, spine, robotics, and traumatology. They also have expertise in digital health, offering solutions in telemedicine, risk management, and surgical planning. Their business model focuses on continuous improvement to provide high-quality products and collaborations with medical professionals to meet their needs. Through research and development, they aim to bring innovative technologies to the healthcare industry. Overall, Medacta Group SA offers a wide range of products and services tailored to the needs of healthcare professionals and patients, establishing themselves as a leading company in the medical technology industry.
The expected revenue of Medacta Group is 765.51 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Medacta Group is 98.64 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Medacta Group is currently 24.98. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Medacta Group stock.
The price-to-sales ratio (P/S) of Medacta Group is currently 3.22. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Medacta Group stock.
The Eulerpool Quality Score for Medacta Group is 6/10.
The ISIN of Medacta Group is CH0468525222. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Medacta Group is A2PFTD. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Medacta Group is MOVE.SW. The ticker symbol is used to trade Medacta Group shares on the stock exchange.
Medacta Group stock
Medacta Group Peer Group
Medacta Group Ticker
Medacta Group FIGI
All fundamentals and in-depth analysis of Medacta Group
Our stock analysis for Medacta Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medacta Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.